WARNING: MYELOSUPPRESSION HYCAMTIN can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts of greater than or equal to 1,500/mm 3 and platelet counts greater than or equal to 100,000/mm 3. Monitor blood cell counts [see Warnings and Precautions (5.1)]. WARNING: MYELOSUPPRESSION See full prescribing information for complete boxed warning.
HYCAMTIN can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts greater than or equal to 1,500/mm 3 and platelet counts greater than or equal to 100,000/mm 3. Monitor blood cell counts (2.4, 5.1).
Use: Labeled indications
- Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent
- Patients with small cell lung cancer (SCLC) platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy, as a single agent
- Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin
Full indications and usage US FDA label
1 INDICATIONS AND USAGE HYCAMTIN for injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent (1.1) Patients with small cell lung cancer (SCLC) platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy, as a single agent (1.2) Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin (1.3) 1.1 Ovarian Cancer HYCAMTIN ® for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. 1.2 Small Cell Lung Cancer HYCAMTIN for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first‑line chemotherapy. 1.3 Cervical Cancer HYCAMTIN for injection, in combination with cisplatin, is indicated for the treatment of patients with Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment.
Contraindications
4 CONTRAINDICATIONS HYCAMTIN is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. Reactions have included anaphylactoid reactions [see Adverse Reactions (6.2)]. History of severe hypersensitivity reactions to topotecan (4)
US FDA labelDosing: Adult
- Ovarian Cancer and Small Cell Lung Cancer: 1.5 mg/m 2 by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day cycle (2.2, 2.3)
- Cervical Cancer: 0.75 mg/m 2 by intravenous infusion over 30 minutes on Days 1, 2, and 3, with cisplatin 50 mg/m 2 on Day 1, of a 21-day cycle (2.4)
- Renal Impairment: Reduce dose if creatinine clearance (CLcr) 20 to 39 mL/min (2.6)
2.1 Important Safety Information
2.1 Important Safety Information Verify dosage using body surface area. Do not exceed a single dose of 4 mg intravenously.
2.2 Recommended Dosage for Ovarian Cancer
2.2 Recommended Dosage for Ovarian Cancer The recommended dosage of HYCAMTIN for injection is 1.5 mg/m 2 by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity.
2.3 Recommended Dosage for Small Cell Lung Cancer (SCLC)
2.3 Recommended Dosage for Small Cell Lung Cancer (SCLC) The recommended dosage of HYCAMTIN for injection is 1.5 mg/m 2 by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day cycle.
2.4 Recommended Dosage for Cervical Cancer
2.4 Recommended Dosage for Cervical Cancer The recommended dosage of HYCAMTIN for injection is 0.75 mg/m 2 by intravenous infusion over 30 minutes daily on Days 1, 2, and 3, in combination with cisplatin 50 mg/m 2 on Day 1, of a 21-day cycle.
2.5 Dosage Modifications for Adverse Reactions Hematologic
2.5 Dosage Modifications for Adverse Reactions Hematologic Do not administer subsequent cycles of HYCAMTIN for injection until neutrophils recover to greater than 1,000/mm 3, platelets recover to greater than 100,000/mm 3, and hemoglobin levels recover to greater than or equal to 9 g/dL (with transfusion if necessary). For HYCAMTIN for injection as a single agent, reduce the dose to 1.25 mg/m 2 /day for: neutrophil counts of less than 500/mm 3 or administer granulocyte-colony stimulating factor (G-CSF) starting no sooner than 24 hours following the last dose platelet counts less than 25,000/mm 3 during previous cycle For HYCAMTIN for injection in combination with cisplatin, reduce the dose to 0.6 mg/m 2 /day (and further to 0.45 mg/m 2 if necessary) for: febrile neutropenia (defined as neutrophil counts less than 1,000/mm 3 with temperature of greater than or equal to 38.0°C (100.4°F) or administer G-CSF starting no sooner than 24 hours following the last dose platelet counts less than 25,000/mm 3 during previous cycle
2.6 Dosage Modification for Renal Impairment
2.6 Dosage Modification for Renal Impairment For HYCAMTIN for injection as a single agent, reduce the dose to 0.75 mg/m 2 /day for patients with creatinine clearance (CLcr) of 20 to 39 mL/min (calculated with the Cockcroft-Gault method using ideal body weight) [see Clinical Pharmacology (12.3)].
2.7 Preparation and Intravenous Administration
2.7 Preparation and Intravenous Administration Visually inspect for particulate matter and discoloration prior to administration, whenever solution and container permit. Preparation Reconstitute each 4 mg vial of HYCAMTIN for injection with 4 mL Sterile Water for Injection, USP. Dilute the appropriate volume of the reconstituted solution in either 0.9% Sodium Chloride Intravenous Infusion, USP or 5% Dextrose in Water Injection, USP.
Stability Because the vials contain no preservative, use contents immediately after reconstitution. Discard any unused portion. Store reconstituted product diluted for infusion at approximately 20°C to 25°C (68°F to 77°F) protected from light for no more than 24 hours. Discard after 24 hours. HYCAMTIN for injection is a cytotoxic drug.
Follow applicable handling and disposal procedures. 1
Dosing: Altered kidney function
2.6 Dosage Modification for Renal Impairment For HYCAMTIN for injection as a single agent, reduce the dose to 0.75 mg/m 2 /day for patients with creatinine clearance (CLcr) of 20 to 39 mL/min (calculated with the Cockcroft-Gault method using ideal body weight) [see Clinical Pharmacology (12.3)].
8.6 Renal Impairment Reduce the dose of HYCAMTIN for injection in patients with a CLcr of 20 to 39 mL/min [see Dosage and Administration (2.6), Clinical Pharmacology (12.3)]. No dosage adjustment is recommended for patients with CLcr greater than or equal to 40 mL/min. Insufficient data are available in patients with CLcr less than 20 mL/min to provide a dosage recommendation for HYCAMTIN for injection.
Patients with Renal Impairment Compared to patients with CLcr (calculated by the Cockcroft-Gault method using ideal body weight) greater than 60 mL/min, plasma clearance of topotecan lactone decreased by 33% in patients with CLcr 40-60 mL/min and decreased 65% in patients with CLcr 20-39 mL/min. The effect on topotecan pharmacokinetics in patients with CLcr less than 20 mL/min is unknown [see Dosage and Administration (2.6)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the 879 patients with metastatic ovarian cancer or small cell lung cancer in clinical trials of HYCAMTIN for injection, 32% were aged 65 years and older, while 3.8% were aged 75 years and older. Of the 140 patients with Stage IV-B, relapsed, or refractory cervical cancer in clinical trials of HYCAMTIN for injection who received HYCAMTIN with cisplatin in the randomized clinical trial, 6% were aged 65 years and older, while 3% were aged 75 years and older.
No overall differences in effectiveness or safety were observed between these patients and younger patients and other reported clinical experience has not identified differences in responses between the elderly and younger patients.
Administration
2.7 Preparation and Intravenous Administration Visually inspect for particulate matter and discoloration prior to administration, whenever solution and container permit. Preparation Reconstitute each 4 mg vial of HYCAMTIN for injection with 4 mL Sterile Water for Injection, USP. Dilute the appropriate volume of the reconstituted solution in either 0.9% Sodium Chloride Intravenous Infusion, USP or 5% Dextrose in Water Injection, USP. Stability Because the vials contain no preservative, use contents immediately after reconstitution. Discard any unused portion. Store reconstituted product diluted for infusion at approximately 20°C to 25°C (68°F to 77°F) protected from light for no more than 24 hours. Discard after 24 hours. HYCAMTIN for injection is a cytotoxic drug. Follow applicable handling and disposal procedures. 1
US FDA labelDosage forms
Philippines
- Concentrate solution for iv infusion: 1 mg/mL
- Powder for concentrate solution for infusion: 2.5 mg, 4 mg
- Lyophilized powder for concentrate solution fo infusion: 2.5 mg
Registered products in the Philippines
5 products registered with the Food and Drug Administration (FDA) Philippines list Topotecan as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products5
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Topoccord 1Topotecan (as hydrochloride) | 1 mg/mL Concentrate Solution for IV Infusion1 mL in 2 mL-capacity Type I amber glass vial with Fluorotec rubber stopper and royal blue aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Accord Healthcare Limited - Philippine Branch OfficeImporter: Accord Healthcare Limited-Philippine Branch Office | DRP-11008 | Dec 29, 2026 | |
Topoccord 4Topotecan (as hydrochloride) | 1 mg/mL Concentrate Solution for IV Infusion4 mL in 5 mL-capacity Type I amber glass vial with Fluorotec rubber stopper and royal blue aluminum flip off seal (Box of 1's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Accord Healthcare Limited - Philippines BranchImporter: Accord Healthcare Limited-Philippine Branch Office | DRP-11262 | Feb 22, 2027 | |
TopoGetTopotecan (as Hydrochloride) | 2.5 mg Lyophilized Powder for Concentrate Solution fo Infusion (I.V)Type I Clear Glass Vial with gray butyl rubber stopper and sealed with aluminum flip off seal x 10 mL (Box of 1's) | RxVAT-exempt | Venus Remedies Ltd.India | 2MG Incorporated | DRP-18037 | Apr 28, 2031 | |
ToponovaTopotecan (as hydrochloride) | 2.5mg Powder for Concentrate Solution for Infusion10 mL-capacity Type I clear tubular glass vial with 20 mm grey butyl rubber plug and 20 mm off-white aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Medinova Pharmaceutical Inc. | DR-XY48774 | Jun 13, 2028 | |
ToponovaTopotecan (as hydrochloride) | 4mg Powder for Concentrate Solution for Infusion17 mL-capacity Type I Clear tubular glass vial with 20 mm grey butyl rubber stopper and 20mm black aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Venus Remedies, Limited.India | Medinova Pharmaceutical Inc. | DR-XY49024 | Mar 22, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS For injection: 4 mg (free base) of topotecan as a light yellow to greenish lyophilized powder in single-dose vial for reconstitution. For injection: 4 mg (free base) lyophilized powder in single-dose vial (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Interstitial Lung Disease (ILD): Fatal cases have occurred. Permanently discontinue if ILD confirmed. (5.2)
- Extravasation and Tissue Injury: Severe cases have occurred. If extravasation occurs, immediately stop administration and institute recommended management procedures. (5.3)
- Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of potential risk to the fetus and to use effectives contraception. (5.4, 8.1, 8.3)
5.1 Myelosuppression
5.1 Myelosuppression HYCAMTIN can cause severe myelosuppression. Single Agent Grade 4 neutropenia occurred in 78% of 879 patients, with a median duration of 7 days and was most common during Cycle 1 (58% of patients). Grade 4 neutropenia associated with infection occurred in 13% and febrile neutropenia occurred in 5%. Sepsis occurred in 4% of patients and was fatal in 1%.
Grade 4 thrombocytopenia occurred in 27%, with a median duration of 5 days. Grade 3 or 4 anemia occurred in 37% of patients. Combination with Cisplatin Grade 4 neutropenia occurred in 48% and Grade 4 thrombocytopenia occurred in 7% of 147 patients. Grade 3 or 4 anemia occurred in 40% of patients. Topotecan can cause fatal typhlitis (neutropenic enterocolitis).
Consider the possibility of typhlitis in patients presenting with fever, neutropenia, and abdominal pain. Administer the first cycle of HYCAMTIN for injection only to patients with a baseline neutrophil count of greater than or equal to 1,500/mm 3 and a platelet count greater than or equal to 100,000/mm 3. Monitor blood counts frequently during treatment.
Withhold and reduce dose of HYCAMTIN for injection based on neutrophil counts, platelet counts and hemoglobin levels [see Dosage and Administration (2.5)].
5.2 Interstitial Lung Disease
5.2 Interstitial Lung Disease Interstitial lung disease (ILD), including fatalities, can occur with HYCAMTIN. Underlying risk factors include history of ILD, pulmonary fibrosis, lung cancer, thoracic radiation, and use of pneumotoxic drugs or colony stimulating factors. Monitor for pulmonary symptoms indicative of ILD. Permanently discontinue HYCAMTIN for injection if ILD is confirmed.
5.3 Extravasation and Tissue Injury
5.3 Extravasation and Tissue Injury Extravasation, including severe cases, can occur with HYCAMTIN for injection. If signs or symptoms of extravasation occur, immediately stop administration of HYCAMTIN for injection and institute recommended management procedures [see Adverse Reactions (6.1)].
5.4 Embryo-Fetal Toxicity
5.4 Embryo-Fetal Toxicity Based on animal data, HYCAMTIN can cause fetal harm when administered to a pregnant woman. Topotecan caused embryolethality, fetotoxicity, and teratogenicity in rats and rabbits when administered during organogenesis. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose of HYCAMTIN for injection.
Advise males with a female partner of reproductive potential to use effective contraception during treatment with HYCAMTIN for injection and for 3 months after the last dose [see Use in Specific Populations (8.1, 8.3), Nonclinical Toxicology (13.1)].
Drug interactions
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
In Vitro Studies Topotecan does not inhibit CYP1A2, CYP2A6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E, CYP3A, or CYP4A or dihydropyrimidine dehydrogenase.
Adverse reactions
- The following serious adverse reactions are described elsewhere in the labeling: Myelosuppression [see Warnings and Precautions (5.1)] Interstitial Lung Disease (ILD) [see Warnings and Precautions (5.2)] Extravasation and Tissue Injury [see Warnings and Precautions (5.3)] Ovarian Cancer The most common Grade 3 or 4 hematologic adverse reactions (incidence > 5%) were neutropenia, anemia, thrombocytopenia, and febrile neutropenia. (6.1)
- The most common (incidence > 5%) non-hematologic adverse reactions (all Grades) were nausea, vomiting, fatigue, diarrhea, and dyspnea. (6.1)
- SCLC The most common Grade 3 or 4 hematologic adverse reactions were (incidence > 5%) neutropenia, anemia, thrombocytopenia, and febrile neutropenia. (6.1)
- The most common (incidence > 5%) non-hematologic adverse reactions (all Grades) were asthenia, dyspnea, nausea, pneumonia, abdominal pain, and fatigue. (6.1)
- Cervical Cancer The most common Grade 3 or 4 hematologic adverse reactions were (incidence > 5%) neutropenia, anemia, and thrombocytopenia. (6.1)
- The most common (incidence > 25% and ≥ 2% higher than cisplatin alone) non-hematologic adverse reactions were pain, vomiting, and infection/febrile neutropenia. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data in Warnings and Precautions reflect exposure to HYCAMTIN for injection from eight trials in which 879 patients with ovarian cancer or small cell lung cancer (SCLC) received HYCAMTIN for injection 1.5 mg/m 2 by intravenous infusion daily for 5 consecutive days, starting on Day 1 of a 21 day cycle and from one trial (Study GOG 0179) in which 147 patients with cervical cancer received HYCAMTIN for injection 0.75 mg/m 2 by intravenous infusion daily on Days 1, 2, and 3, with cisplatin 50 mg/m 2 by intravenous infusion on Day 1, of a 21-day cycle.
Ovarian Cancer The safety of HYCAMTIN for injection was evaluated in a randomized trial conducted in 226 patients with metastatic ovarian cancer (Study 039) [see Clinical Studies (14.1)]. Table 1 shows the incidence of Grade 3 and 4 hematologic and non-hematologic adverse reactions that occurred in patients receiving HYCAMTIN for injection.
Table 1. Adverse Reactions Occurring in Greater than or Equal to 5% of Patients With Ovarian Cancer in Study 039 a Death related to sepsis occurred in 2% of patients receiving HYCAMTIN and 0% of patients receiving paclitaxel. b Pain includes body pain, skeletal pain, and back pain. Adverse Reactions HYCAMTIN for Injection (n = 112) Paclitaxel (n = 114) Grade 3-4 (%) Grade 3-4 (%) Hematologic Grade 4 neutropenia (< 500/mm 3) Grade 3 or 4 anemia (Hgb < 8 g/dL) Grade 4 thrombocytopenia (< 25,000/mm 3) Febrile neutropenia 80 41 27 23 21 6 3 4 Non-Hematologic Infections Sepsis a 5 2 Respiratory, thoracic, and mediastinal Dyspnea 6 5 Gastrointestinal Vomiting 10 3 Nausea 10 2 Diarrhea 6 1 Abdominal pain 5 4 Intestinal obstruction 5 4 Constipation 5 0 General and administrative site conditions Fatigue 7 6 Pain b 5 7 Asthenia 5 3 Small Cell Lung Cancer (SCLC) The safety of HYCAMTIN for injection was evaluated in randomized, comparative trial in patients with recurrent or progressive SCLC (Study 090) [see Clinical Studies (14.2)].
Table 2 shows the Grade 3 or 4 hematologic and non-hematologic adverse reactions in patients with SCLC. Table 2. Adverse Reactions Occurring in Greater than or Equal to 5% of Patients With Small Cell Lung Cancer in Study 090 a Death related to sepsis occurred in 3% of patients receiving HYCAMTIN and 1% of patients receiving CAV. b Pain includes body pain, skeletal pain, and back pain. c CAV = cyclophosphamide, doxorubicin and vincristine.
Adverse Reactions HYCAMTIN for Injection (n = 107) CAV c (n = 104) Grade 3-4 (%) Grade 3-4 (%) Hematologic Grade 4 neutropenia (< 500/mm 3) Grade 3 or 4 anemia (Hgb < 8 g/dL) Grade 4 thrombocytopenia (< 25,000/mm 3) Febrile neutropenia 70 42 29 28 72 20 5 26 Non-Hematologic Infections Sepsis a 5 5 Respiratory, thoracic, and mediastinal Dyspnea 9 14 Pneumonia 8 6 Gastrointestinal Nausea 8 6 Abdominal pain 6 4 General and administrative site conditions Asthenia 9 7 Fatigue 6 10 Pain b 5 7 Hepatobiliary Disorders in Ovarian and Small Cell Lung Cancer (SCLC) Based on the combined experience of 453 patients with metastatic ovarian cancer and 426 patients with SCLC treated with HYCAMTIN for injection, Grade 3 or 4 increases aspartate transaminase (AST) or alanine transaminase (ALT) occurred in 4% and Grade 3 or 4 elevated bilirubin occurred in less than 2%. Cervical Cancer The safety of HYCAMTIN for injection was evaluated in a comparative trial of HYCAMTIN with cisplatin versus cisplatin as a single agent in patients with cervical cancer (Study GOG 0179).
Table 3 shows the hematologic and non-hematologic adverse reactions in patients with cervical cancer. Table 3. Adverse Reactions Occurring in Greater than or Equal to 5% of Patients With Cervical Cancer (Between-Arm Difference ≥ 2%) a in Study GOG 0179 a Includes patients who were eligible and treated. b Severity based on using National Cancer Institute (NCI) Common Toxicity Criteria (CTC), Version 2.0. c Grades 1 through 4 only.
There were 3 patients who experienced deaths with investigator-designated attribution. The first patient experienced a Grade 5 hemorrhage in which the drug-related thrombocytopenia aggravated the event. A second patient experienced bowel obstruction, cardiac arrest, pleural effusion, and respiratory failure which were not treatment-related but probably aggravated by treatment.
A third patient experienced a pulmonary embolism and adult respiratory distress syndrome; the latter was indirectly treatment-related. d Constitutional includes fatigue (lethargy, malaise, asthenia), fever (in the absence of neutropenia), rigors, chills, sweating, and weight gain or loss. e Pain includes abdominal pain or cramping, arthralgia, bone pain, chest pain (non-cardiac and non-pleuritic), dysmenorrhea, dyspareunia, earache, headache, hepatic pain, myalgia, neuropathic pain, pain due to radiation, pelvic pain, pleuritic pain, rectal or perirectal pain, and tumor pain. f High-level terms were included if the between-arm difference was ≥ 10%. Adverse Reactions HYCAMTIN for Injection With Cisplatin (n = 140) % Cisplatin (n = 144) % Hematologic Neutropenia Grade 3 (< 1,000-500/mm 3) 26 1 Grade 4 (< 500/mm 3) 48 1 Anemia Grade 3 (Hgb < 8-6.5 g/dL) 34 19 Grade 4 (Hgb < 6.5 g/dL) 6 3 Thrombocytopenia Grade 3 (< 50,000-10,000/mm 3) 26 3 Grade 4 (< 10,000/mm 3) 7 0 Non-Hematologic b,c General and administrative site conditions Constitutional d 69 62 Pain e 59 50 Gastrointestinal Vomiting 40 37 Stomatitis-pharyngitis 6 0 Other 63 56 Dermatology f 48 20 Infection Febrile neutropenia f 28 18 Cardiovascular f 25 15
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following reactions have been identified during post approval use of HYCAMTIN. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic System: severe bleeding (in association with thrombocytopenia) Hypersensitivity: allergic manifestations, anaphylactoid reactions, angioedema Gastrointestinal: abdominal pain potentially associated with neutropenic enterocolitis, gastrointestinal perforation Pulmonary: interstitial lung disease Skin and Subcutaneous Tissue: severe dermatitis, severe pruritus General and Administration Site Conditions: extravasation, mucosal inflammation
Adverse reaction frequency tables (US label) US FDA label
| aDeath related to sepsis occurred in 2% of patients receiving HYCAMTIN and 0% of patients receiving paclitaxel. bPain includes body pain, skeletal pain, and back pain. | ||
| Adverse Reactions | HYCAMTIN for Injection(n = 112) | Paclitaxel(n = 114) |
| Grade 3-4 (%) | Grade 3-4 (%) | |
| Hematologic | ||
| Grade 4 neutropenia (< 500/mm3) Grade 3 or 4 anemia (Hgb < 8 g/dL) Grade 4 thrombocytopenia (< 25,000/mm3) Febrile neutropenia | 80 41 27 23 | 21 6 3 4 |
| Non-Hematologic | ||
| Infections | ||
| Sepsisa | 5 | 2 |
| Respiratory, thoracic, and mediastinal | ||
| Dyspnea | 6 | 5 |
| Gastrointestinal | ||
| Vomiting | 10 | 3 |
| Nausea | 10 | 2 |
| Diarrhea | 6 | 1 |
| Abdominal pain | 5 | 4 |
| Intestinal obstruction | 5 | 4 |
| Constipation | 5 | 0 |
| General and administrative site conditions | ||
| Fatigue | 7 | 6 |
| Painb | 5 | 7 |
| Asthenia | 5 | 3 |
| aDeath related to sepsis occurred in 3% of patients receiving HYCAMTIN and 1% of patients receiving CAV. bPain includes body pain, skeletal pain, and back pain. cCAV = cyclophosphamide, doxorubicin and vincristine. | ||
| Adverse Reactions | HYCAMTIN for Injection(n = 107) | CAVc(n = 104) |
| Grade 3-4 (%) | Grade 3-4 (%) | |
| Hematologic | ||
| Grade 4 neutropenia (< 500/mm3) Grade 3 or 4 anemia (Hgb < 8 g/dL) Grade 4 thrombocytopenia (< 25,000/mm3) Febrile neutropenia | 70 42 29 28 | 72 20 5 26 |
| Non-Hematologic | ||
| Infections | ||
| Sepsisa | 5 | 5 |
| Respiratory, thoracic, and mediastinal | ||
| Dyspnea | 9 | 14 |
| Pneumonia | 8 | 6 |
| Gastrointestinal | ||
| Nausea | 8 | 6 |
| Abdominal pain | 6 | 4 |
| General and administrative site conditions | ||
| Asthenia | 9 | 7 |
| Fatigue | 6 | 10 |
| Painb | 5 | 7 |
| aIncludes patients who were eligible and treated. bSeverity based on using National Cancer Institute (NCI) Common Toxicity Criteria (CTC), Version 2.0. cGrades 1 through 4 only. There were 3 patients who experienced deaths with investigator-designated attribution. The first patient experienced a Grade 5 hemorrhage in which the drug-related thrombocytopenia aggravated the event. A second patient experienced bowel obstruction, cardiac arrest, pleural effusion, and respiratory failure which were not treatment-related but probably aggravated by treatment. A third patient experienced a pulmonary embolism and adult respiratory distress syndrome; the latter was indirectly treatment-related. dConstitutional includes fatigue (lethargy, malaise, asthenia), fever (in the absence of neutropenia), rigors, chills, sweating, and weight gain or loss. ePain includes abdominal pain or cramping, arthralgia, bone pain, chest pain (non-cardiac and non-pleuritic), dysmenorrhea, dyspareunia, earache, headache, hepatic pain, myalgia, neuropathic pain, pain due to radiation, pelvic pain, pleuritic pain, rectal or perirectal pain, and tumor pain. fHigh-level terms were included if the between-arm difference was ≥ 10%. | ||
| Adverse Reactions | HYCAMTIN for Injection With Cisplatin(n = 140) % | Cisplatin(n = 144) % |
| Hematologic | ||
| Neutropenia | ||
| Grade 3 (< 1,000-500/mm3) | 26 | 1 |
| Grade 4 (< 500/mm3) | 48 | 1 |
| Anemia | ||
| Grade 3 (Hgb < 8-6.5 g/dL) | 34 | 19 |
| Grade 4 (Hgb < 6.5 g/dL) | 6 | 3 |
| Thrombocytopenia | ||
| Grade 3 (< 50,000-10,000/mm3) | 26 | 3 |
| Grade 4 (< 10,000/mm3) | 7 | 0 |
| Non-Hematologicb,c | ||
| General and administrative site conditions | ||
| Constitutionald | 69 | 62 |
| Paine | 59 | 50 |
| Gastrointestinal | ||
| Vomiting | 40 | 37 |
| Stomatitis-pharyngitis | 6 | 0 |
| Other | 63 | 56 |
| Dermatologyf | 48 | 20 |
| Infection | ||
| Febrile neutropeniaf | 28 | 18 |
| Cardiovascularf | 25 | 15 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on animal data and its mechanism of action, HYCAMTIN can cause fetal harm when administered to a pregnant woman. There are no available clinical data on the use of HYCAMTIN in pregnancy. Topotecan caused embryolethality, fetotoxicity, and teratogenicity in rats and rabbits when administered during organogenesis at doses similar to the clinical dose (see Data).
Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. Data Animal Data In rabbits, an intravenous dose of 0.10 mg/kg/day [about equal to the 1.5 mg/m 2 clinical dose based on body surface area (BSA)] given on Days 6 through 20 of gestation caused maternal toxicity, embryolethality and reduced fetal body weight.
In the rat, an intravenous dose of 0.23 mg/kg/day (about equal to the 1.5 mg/m 2 clinical dose based on BSA) given for 14 days before mating through gestation Day 6 caused fetal resorption, microphthalmia, pre-implant loss, and mild maternal toxicity. Administration of an intravenous dose of 0.10 mg/kg/day (about half the 1.5 mg/m 2 clinical dose based on BSA) given to rats on Days 6 through 17 of gestation caused an increase in post-implantation mortality.
This dose also caused an increase in total fetal malformations. The most frequent malformations were of the eye (microphthalmia, anophthalmia, rosette formation of the retina, coloboma of the retina, ectopic orbit), brain (dilated lateral and third ventricles), skull, and vertebrae.
Mechanism of action
12.1 Mechanism of Action Topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks. Topotecan binds to the topoisomerase I‑DNA complex and prevents re-ligation of these single-strand breaks. The cytotoxicity of topotecan is thought to be due to double-strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double-strand breaks.
US FDA labelPharmacokinetics
Elimination The terminal half-life of topotecan is 2 to 3 hours following intravenous administration.
Excretion The overall recovery of total topotecan and its N-desmethyl metabolite in urine and feces over 9 days averaged 73% ± 2% following an intravenous dose.
Mean values of 51% ± 3% as total topotecan and 3% ± 1% as N-desmethyl topotecan were excreted in the urine.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Following administration of HYCAMTIN for injection at doses of 0.5 to 1.5 mg/m 2 (0.1 to 0.3 times the recommended single agent dose) administered as a 30-minute infusion, area under the curve (AUC) increases proportionally with dose. Distribution Protein binding of topotecan is approximately 35%. Elimination The terminal half-life of topotecan is 2 to 3 hours following intravenous administration.
Metabolism Topotecan undergoes a reversible pH-dependent hydrolysis of its pharmacologically active lactone moiety. At pH less than or equal to 4, the lactone is exclusively present, whereas the ring-opened hydroxy-acid form predominates at physiologic pH. Topotecan is metabolized to an N-demethylated metabolite in vitro.
The mean metabolite: parent AUC ratio was about 3% for total topotecan and topotecan lactone following intravenous administration. Excretion The overall recovery of total topotecan and its N-desmethyl metabolite in urine and feces over 9 days averaged 73% ± 2% following an intravenous dose. Mean values of 51% ± 3% as total topotecan and 3% ± 1% as N-desmethyl topotecan were excreted in the urine.
Fecal elimination of total topotecan accounted for 18% ± 4% while fecal elimination of N-desmethyl topotecan was 1.7% ± 0.6%. An O-glucuronidation metabolite of topotecan and N-desmethyl topotecan has been identified in the urine. Specific Populations No clinically significant differences in the pharmacokinetics of topotecan were observed based on age, sex, or hepatic impairment following intravenous administration.
Patients with Renal Impairment Compared to patients with CLcr (calculated by the Cockcroft-Gault method using ideal body weight) greater than 60 mL/min, plasma clearance of topotecan lactone decreased by 33% in patients with CLcr 40-60 mL/min and decreased 65% in patients with CLcr 20-39 mL/min. The effect on topotecan pharmacokinetics in patients with CLcr less than 20 mL/min is unknown [see Dosage and Administration (2.6)].
Drug Interaction Studies Clinical Studies No clinically significant changes in topotecan pharmacokinetics were observed when coadministered cisplatin. No clinically significant changes in the pharmacokinetics of free platinum were observed in patients coadministered cisplatin with topotecan. In Vitro Studies Topotecan does not inhibit CYP1A2, CYP2A6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E, CYP3A, or CYP4A or dihydropyrimidine dehydrogenase.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. HYCAMTIN · Novartis Pharmaceuticals Corporation [US FDA-approved label, version 8, July 7, 2022]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eeee060c-a9ec-423e-a374-8484009f8524
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .